James D. Cox, former RTOG chair, dies at 80

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jim Cox, professor emeritus in radiation oncology at the University of Texas MD Anderson Cancer Center, passed away on Aug. 14. He was 80.

A native of Ohio, Jim graduated with honors from Kenyon College and University of Rochester School of Medicine and Dentistry and completed his oncology training at Penrose Cancer Hospital of Colorado Springs, University of Chicago, and Institute Gustav Roussy Institute in France.

Jim served during his long and illustrious career as professor and founding chairman of the departments of radiation oncology at Medical College of Wisconsin and Columbia University College of Physicians and Surgeons and as professor, physician-in-chief, and division of radiation oncology head at UTMDACC.

In each of these roles, Jim had extraordinary success in mentoring younger physicians, elevating the care of cancer patients and the associated clinical and translational research, and establishing a culture of collaborative inquiry among his colleagues.

I personally came to know Jim best during his tenure (1987-1997) as Group Chairman of the Radiation Therapy Oncology Group. RTOG was at that time one of ten NCI-supported cooperative groups and was struggling in the late 1980’s with its identify and core research mission.

Jim significantly expanded the core membership of RTOG to include surgeons, medical oncologists, medical physicists, translational and computational scientists, and international investigators.

The group became one of the first truly multi-disciplinary cooperative groups and began to more fully fulfill its mission of improving the lives of adults with localized or locally advanced malignancies through the conduct of its clinical trials.

I had the honor of serving as the RTOG Brain Tumor Committee Chairman and RTOG Deputy Group Chairman during the latter years of Jim’s term as Group Chairman and succeeding him in that role.

Jim was an extraordinary mentor for me and for literally hundreds of other professionals he touched during his career. He had a very intuitive feel as to when to step back and when to push and when to shout out and when to remain silent, whether the issue was with other investigators, other cooperative groups, staff, or the NCI.

He was invaluable as RTOG Past Group Chairman to the group in strategizing as to how to successfully function as an undercapitalized, underappreciated research organization through a highly politicized environment.

Jim had a wonderful sense of humor, smile, and laugh, and the most melodious public speaking voice this side of Humphrey Bogart. He loved all things French and all the richness that travel and arts can bring to a great life. He was devoted to and is survived by his wife and colleague Ritsuko Komaki, MD, his children Lara and Christoph Cox, and his five grandchildren.

The author is the group chairman and principal investigator of NRG Oncology, formerly the Radiation Therapy Oncology Group, and executive director of Winship Cancer Institute of Emory University

Group chairman and principal investigator, NRG Oncology
Executive director, Winship Cancer Institute of Emory University
In This Issue


President Joe Biden’s proposed Advanced Research Projects Agency-Health would be a welcome partner to NCI—particularly in conducting large, collaborative clinical investigations, NCI Director Ned Sharpless said.“I think having ARPA-H as part of the NIH is good for the NCI,” Sharpless said April 11 in his remarks at the annual meeting of the American Association for Cancer Research. “How this would fit with the ongoing efforts in cancer at the NCI is still something to work out.”
Group chairman and principal investigator, NRG Oncology
Executive director, Winship Cancer Institute of Emory University